Back to results
US 8,148,074 B2Granted
IRF-5 haplotypes in systemic lupus erythematosus
AssigneesRegents of the University of Minnesota, The General Hospital Corporation
InventorsTimothy W. Behrens, Robert R. Graham, David Altshuler
Life of this patent
Estimating the term…
Abstract
Methods and materials involved in diagnosing SLE are provided herein. The methods and materials can be used to diagnose SLE and/or assess a mammal's susceptibility to develop SLE, based on the presence or absence of one or more IRF-5 variants.
Claims4
A method for assessing the predisposition of a human to develop systemic lupus erythematosus (SLE), comprising:
- (a) assaying nucleic acid from a biological sample of said human to determine whether or not said human has an IRF-5 haplotype comprising an rs2004640 T allele, the 30 base pair IRF-5 exon 6 insertion allele depicted in FIG. 11 herein, and an rs10954213 A allele;
- and
- (b) classifying said human as being predisposed to develop SLE if said human has said IRF-5 haplotype, or classifying said human as not being predisposed to develop SLE if said human does not contain said IRF-5 haplotype.
A method for assessing the predisposition of a human to develop SLE, comprising:
- (a) assaying nucleic acid from a biological sample of said human to determine whether or not said human has an IRF-5 haplotype comprising an rs2004640 T allele, the 30 base pair IRF-5 exon 6 insertion allele depicted in FIG. 11 herein, an rs10954213 A allele, and an rs2070197 C allele;
- and
- (b) classifying said human as being predisposed to develop SLE if said human has said IRF-5 haplotype, or classifying said human as not being predisposed to develop SLE if said human does not have said IRF-5 haplotype.
Dependencies are inferred from the claim text.